{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-25-000188","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2025-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.824669+00:00","generated_at":"2026-05-17T06:51:49.201986+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Emergent gets $56M ACAM2000 contract modification; 2025 sales projected >$120M","bullets":["Contract Modification No. 14 valued at $56M; deliveries to U.S. government by Dec 31, 2025.","Total 2025 projected sales for ACAM2000 and ancillary products exceed $120M from diverse customer base.","ACAM2000 is FDA-approved for smallpox (2007) and mpox (Aug 2024); also licensed in Canada, Australia, Singapore.","Modification exercises Option Year 6 under existing 10-year ASPR contract (75A50119C00071)."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-25-000188","json":"https://secwatch.observer/filing/0001367644-25-000188.json","markdown":"https://secwatch.observer/filing/0001367644-25-000188.md","text":"https://secwatch.observer/filing/0001367644-25-000188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000188/0001367644-25-000188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000188/ebs-20250905.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:51:49.201986+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}